ValiRx is a parent company to a growing portfolio of Special Purpose Vehicle companies (SPVs). The structure and purpose of each is unique and optimised per project.
We incubate preclinical projects in-house until they are placed in the SPV subsidiaries, ready for partnership.
ValiSeek Limited is an early example of our SPV model.
ValiSeek is ValiRx's Joint Venture Company, formed with Tangent Reprofiling Limited (a SEEK group company) in 2014 with the purpose of rapidly progressing VAL401 through development. ValiRx currently holds 55% of ValiSeek.
VAL401 has now successfully completed a pilot Phase 2 clinical trial and ValiSeek is seeking external partners to continue clinical development.